Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 25 April 2017


GAMUNEX-C is an immune globulin injection (human), 10% liquid indicated for treatment of:
• Primary Humoral Immunodeficiency (PI) in patients 2 years of age and older (1.1)
• Idiopathic Thrombocytopenic Purpura (ITP) (1.2)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (1.3)

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

Advisory information

• Anaphylactic or severe systemic reactions to human immunoglobulin (4.1)
• IgA deficient patients with antibodies against IgA and a history of hypersensitivity (4.2)
Special warnings and precautions

See full prescribing information for complete boxed warning.
• Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
• For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
• Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients.
• Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMUNEX-C does not contain sucrose.
• For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. (5.2)

• IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions. (5.1)
• Hyperproteinemia, with resultant changes in serum viscosity and electrolyte imbalances may occur in patients receiving IGIV therapy. (5.3)
• Aseptic Meningitis Syndrome (AMS) has been reported with GAMUNEX-C and other IGIV treatments, especially with high doses or rapid infusion. (5.5)
• Hemolysis, either intravascular or due to enhanced RBC sequestration, can develop subsequent to GAMUNEX-C treatments. Risk factors include high doses and non-O blood group. Monitor patients for hemolysis and hemolytic anemia. (5.6)
• Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). (5.7)
• Volume overload. (5.8)
• GAMUNEX-C is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob (CJD) disease agent. (5.9)
• GAMUNEX-C is not approved for subcutaneous use in ITP patients. Due to a potential risk of hematoma formation, do not administer GAMUNEX-C subcutaneously in patients with ITP. (5.10)
• Passive transfer of antibodies may confound serologic testing. (5.12)

Adverse reactions
The most common adverse reactions observed in ≥ 5% patients were (6.1):
PI: Intravenous: Headache, cough, injection site reaction, nausea, pharyngitis and urticaria.
Subcutaneous: Infusion site reactions, headache, influenza, fatigue, arthralgia and pyrexia.
ITP: Headache, vomiting, fever, nausea, back pain and rash.
CIDP: Headache, fever, chills, hypertension, rash, nausea and asthenia.

Usage information

Dosing and administration
Intravenous Administration Only: ITP and CIDP
Indication Dose Initial Infusion Rate Maintenance Infusion Rate
(if tolerated)
ITP (2.3) 2 g/kg 1 mg/kg/min 8 mg/kg/min
CIDP (2.4) loading dose 2 g/kg
maintenance dose 1 g/kg
2 mg/kg/min 8 mg/kg/min
Every 3 weeks
• Ensure that patients with pre-existing renal insufficiency are not volume depleted; discontinue GAMUNEX-C if renal function deteriorates. (5.2)
• For patients at risk of renal dysfunction or thrombosis, administer GAMUNEX-C at the minimum infusion rate practicable. (5.2, 5.4)

Intravenous or Subcutaneous Administration: PI (2.2)
Route of
Dose* Initial Infusion Rate Maintenance Infusion Rate
(if tolerated)
Intravenous (IV) 300-600 mg/kg 1 mg/kg/min 8 mg/kg/min
Every 3 to 4 weeks
Subcutaneous (SC) 1.37 x current IV dose in grams/IV dose interval in weeks Adult:† 20 mL/hr/site
Pediatric:†10 mL/hr/site
(< 25 kg)
15 mL/hr/site (≥ 25 kg)
Adult:† 20 ml/hr/site
Pediatric:† 10 mL/hr/site (< 25 kg)
20 mL/hr/site (≥ 25 kg)

* See section 2.2.
† Adults: use up to 8 infusion sites simultaneously; pediatric: use up to 6 infusion sites simultaneously; for all ages, ensure infusion sites are at least 2 inches (5 cm) apart. (2.5)

Use in special populations
• Geriatric: In patients over 65 years of age do not exceed the recommended dose, and infuse GAMUNEX-C at the minimum infusion rate practicable. (8.5)


• The passive transfer of antibodies may transiently interfere with the response to live virus vaccines, such as measles, mumps and rubella. (7)

More information

Category Value
Authorisation number BLA125046
Orphan designation No
Product NDC 13533-800
Date First Approved 13-10-2010
Marketing authorisation holder Grifols Therapeutics Inc.